JMP Securities analyst David Turkaly reiterated a Buy rating on Neuronetics Inc (STIM) today and set a price target of $40. The company’s shares opened today at $16.45, close to its 52-week low of $13.26.
According to TipRanks.com, Turkaly is a 4-star analyst with an average return of 15.5% and a 65.6% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Apyx Medical Corporation, Integra Lifesciences, and Nuvectra Corporation.
Neuronetics Inc has an analyst consensus of Strong Buy, with a price target consensus of $29, which is a 76.3% upside from current levels. In a report issued on February 21, Piper Jaffray also reiterated a Buy rating on the stock with a $35 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.39 and a one-year low of $13.26. Currently, Neuronetics Inc has an average volume of 131.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients.
